CL2017001209A1 - Inhibidor de cinasa aurora a - Google Patents

Inhibidor de cinasa aurora a

Info

Publication number
CL2017001209A1
CL2017001209A1 CL2017001209A CL2017001209A CL2017001209A1 CL 2017001209 A1 CL2017001209 A1 CL 2017001209A1 CL 2017001209 A CL2017001209 A CL 2017001209A CL 2017001209 A CL2017001209 A CL 2017001209A CL 2017001209 A1 CL2017001209 A1 CL 2017001209A1
Authority
CL
Chile
Prior art keywords
kinase inhibitor
aurora kinase
aurora
aminopiridine
cancer
Prior art date
Application number
CL2017001209A
Other languages
English (en)
Inventor
James Robert Henry
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2017001209A1 publication Critical patent/CL2017001209A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO DE AMINOPIRIDINA, O UNA SAL DEL MISMO FARMACÉUTICAMENTE ACEPTABLE, QUE INHIBE A AURORA A Y, POR LO TANTO PUEDE SER ÚTIL EN EL TRATAMIENTO DE CÁNCER.</p>
CL2017001209A 2014-11-14 2017-05-11 Inhibidor de cinasa aurora a CL2017001209A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462079742P 2014-11-14 2014-11-14

Publications (1)

Publication Number Publication Date
CL2017001209A1 true CL2017001209A1 (es) 2018-01-12

Family

ID=54697647

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001209A CL2017001209A1 (es) 2014-11-14 2017-05-11 Inhibidor de cinasa aurora a

Country Status (41)

Country Link
US (2) US9637474B2 (es)
EP (2) EP3473619B8 (es)
JP (1) JP6159029B2 (es)
KR (1) KR101930182B1 (es)
CN (1) CN107108567B (es)
AR (1) AR102463A1 (es)
AU (1) AU2015347043B2 (es)
BR (1) BR112017007239B1 (es)
CA (1) CA2963473C (es)
CL (1) CL2017001209A1 (es)
CO (1) CO2017004784A2 (es)
CR (1) CR20170158A (es)
CY (2) CY1121334T1 (es)
DK (2) DK3473619T3 (es)
DO (1) DOP2017000111A (es)
EA (1) EA032102B1 (es)
EC (1) ECSP17029203A (es)
ES (2) ES2716732T3 (es)
HR (2) HRP20190324T1 (es)
HU (2) HUE043759T2 (es)
IL (1) IL251406B (es)
JO (1) JO3488B1 (es)
LT (2) LT3473619T (es)
ME (1) ME03325B (es)
MX (1) MX2017006275A (es)
MY (1) MY188313A (es)
NZ (1) NZ730771A (es)
PE (1) PE20170898A1 (es)
PH (1) PH12017500881B1 (es)
PL (1) PL3218366T3 (es)
PT (2) PT3218366T (es)
RS (2) RS60999B1 (es)
SG (1) SG11201703394RA (es)
SI (2) SI3473619T1 (es)
SV (1) SV2017005418A (es)
TN (1) TN2017000116A1 (es)
TR (1) TR201902686T4 (es)
TW (1) TWI693218B (es)
UA (1) UA117983C2 (es)
WO (1) WO2016077161A1 (es)
ZA (1) ZA201702199B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210236475A1 (en) * 2018-05-29 2021-08-05 Taiho Pharmaceutical Co., Ltd. Antitumor agent and method for tumor therapy
US20220000855A1 (en) * 2018-11-30 2022-01-06 Eli Lilly And Company An aurora a kinase inhibitor for use in the treatment of neuroblastoma
CN112239465A (zh) 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 极光激酶抑制剂及其用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
AU2022280845A1 (en) 2021-05-24 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
CN117836285A (zh) * 2021-07-28 2024-04-05 北京加科思新药研发有限公司 Aurora a选择性抑制剂的多晶型及其用途
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1956982A (zh) * 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
US8367690B2 (en) * 2009-03-24 2013-02-05 Vertex Pharmaceuticals Inc. Aminopyridine derivatives having aurora a selective inhibitory action
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof

Also Published As

Publication number Publication date
SG11201703394RA (en) 2017-05-30
BR112017007239A2 (pt) 2017-12-19
CY1123592T1 (el) 2022-03-24
CA2963473A1 (en) 2016-05-19
EP3473619B8 (en) 2020-11-04
EP3473619B1 (en) 2020-09-09
PT3218366T (pt) 2019-04-01
MX2017006275A (es) 2017-08-14
LT3473619T (lt) 2020-11-10
AU2015347043A1 (en) 2017-05-04
JO3488B1 (ar) 2020-07-05
TN2017000116A1 (en) 2018-07-04
HRP20190324T1 (hr) 2019-04-19
LT3218366T (lt) 2019-04-10
EP3218366B1 (en) 2019-01-09
HRP20201681T1 (hr) 2020-12-25
BR112017007239B1 (pt) 2023-01-31
ES2716732T3 (es) 2019-06-14
ME03325B (me) 2019-10-20
SI3218366T1 (sl) 2019-02-28
DK3218366T3 (en) 2019-04-01
UA117983C2 (uk) 2018-10-25
PE20170898A1 (es) 2017-07-12
CY1121334T1 (el) 2020-05-29
MY188313A (en) 2021-11-27
AU2015347043B2 (en) 2018-03-22
RS58347B1 (sr) 2019-03-29
RS60999B1 (sr) 2020-11-30
JP6159029B2 (ja) 2017-07-05
US20160137628A1 (en) 2016-05-19
AR102463A1 (es) 2017-03-01
SI3473619T1 (sl) 2020-10-30
CA2963473C (en) 2018-12-18
PH12017500881A1 (en) 2017-11-06
IL251406A0 (en) 2017-05-29
EP3473619A1 (en) 2019-04-24
CR20170158A (es) 2017-06-21
PL3218366T3 (pl) 2019-06-28
EA201790838A1 (ru) 2017-12-29
TWI693218B (zh) 2020-05-11
US9637474B2 (en) 2017-05-02
NZ730771A (en) 2018-07-27
ECSP17029203A (es) 2018-01-31
ZA201702199B (en) 2018-12-19
PH12017500881B1 (en) 2017-11-06
HUE051530T2 (hu) 2021-03-01
SV2017005418A (es) 2018-10-09
CO2017004784A2 (es) 2017-08-31
DOP2017000111A (es) 2017-06-15
JP2016539942A (ja) 2016-12-22
CN107108567A (zh) 2017-08-29
EA032102B1 (ru) 2019-04-30
DK3473619T3 (da) 2020-09-21
PT3473619T (pt) 2020-11-11
CN107108567B (zh) 2020-01-10
WO2016077161A1 (en) 2016-05-19
TR201902686T4 (tr) 2019-03-21
EP3218366A1 (en) 2017-09-20
HUE043759T2 (hu) 2019-09-30
IL251406B (en) 2019-08-29
US10010540B2 (en) 2018-07-03
US20170119751A1 (en) 2017-05-04
KR20170066623A (ko) 2017-06-14
KR101930182B1 (ko) 2018-12-17
TW201629038A (zh) 2016-08-16
ES2826448T3 (es) 2021-05-18

Similar Documents

Publication Publication Date Title
GT201500263A (es) Inhibidores de cdc7
CL2018003511A1 (es) Derivados de pirazolopirimidina como inhibidor de quinasa.
CL2017001209A1 (es) Inhibidor de cinasa aurora a
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CU24389B1 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
ECSP14017584A (es) Compuestos inhibidores de raf
EA201691421A1 (ru) Гетероарилы и их применение
CL2020001749A1 (es) Derivado de amino-metil piperidina como inhibidor de quinasa.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
CO2018013020A2 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
BR112017008481A2 (pt) composto antimicótico
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
PH12017501063A1 (en) Compounds for the treatment of cancer